Brief: Emmaus Life Sciences Announces Collaboration With Kainos Medicine For Preclinical Development Of Irak4 Inhibitor As Potential Anti-Cancer Drug
02/03/2021 18:52
March 2 (Reuters) - Emmaus Life Sciences Inc EMMA.PK :
* EMMAUS LIFE SCIENCES ANNOUNCES COLLABORATION WITH KAINOS
MEDICINE FOR PRECLINICAL DEVELOPMENT OF IRAK4 INHIBITOR AS
POTENTIAL ANTI-CANCER DRUG
Source text for Eikon: ID:nPn2FJp5Qa
Further company coverage: EMMA.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Emmaus Life Sciences
See all newsEmmaus Life Sciences Q2 revenue soars on licensing deal
Emmaus Life Sciences Q1 revenue falls driven by lower sales in U.S.
Brief: Emmaus Life Sciences Enters License And Distribution Agreement With Neoimmunetech
Emmaus Life Sciences Q3 revenue falls 38%, swings to loss
Brief: Emmaus Life Sciences CFO Yasushi Nagasaki Resigns